AstraZeneca PLC (AZN) Stock Falls as FDA Panel Votes Against New Cancer Drug
AstraZeneca PLC (NYSE:AZN) is among the Best Biotech Stocks. On May 1, CNBC reported that an FDA advisory panel voted 6-3 against allowing AstraZeneca PLC (NYSE:AZN)’s oral breast cancer drug camizestrant. This action resulted in the company’s London-listed shares falling 2% Friday morning. Panel members voting against the drug concluded that the SERENA-6 study failed to […]
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.